Monitoring heart rhythms after a heart attack

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of an implantable cardiac monitor (ICM) in patients who have experienced an acute myocardial infarction (AMI) to assess and manage their risk of sudden cardiac death. The study aims to determine if early monitoring can lead to better patient management and outcomes by identifying arrhythmias that may require intervention. Participants will receive standard care along with ICM implantation within 21 days of their AMI. The trial focuses on patients with ventricular tachycardia or fibrillation, who are at higher risk for sudden cardiac death.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults, age 18 years or older
* AMI (STEMI and NSTEMI)
* Willing to give written informed consent
* Expected discharge from hospital within 7 days of AMI
* Willing to receive ICM insertion within 21 days of index AMI

Exclusion Criteria:

* Existing pacemaker, ICD, ICM, or any other implantable cardiac electronic device
* Pregnant
* Index AMI was more than 21 days
* Unwilling/cannot insert ICM within 21 days post AMI
* Planned ICD implant, planned CABG or any open-heart surgery (e.g. for severe valvular disease)

Where it's running

• UPMC Presbyterian Hospital
  Pittsburgh, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Samir F Saba, MD — University of Pittsburgh Medical Center
• Study coordinator: Samir F Saba, MD
• Email: sabas@upmc.edu
• Phone: 412 647 2695

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating a noninvasive tissue sensor to detect cardiogenic shock earlier in heart patients

  This pilot, noninvasive study tests whether the NIRSense wearable can help detect deterioration in adults with cardiogenic shock risk due to heart attack or heart failure.

  Recruiting NIRSense Inc. · Weston, Florida · NCT07825363

• Adenosine given before primary PCI to reduce no-reflow in STEMI patients.

  See if giving intracoronary adenosine before primary PCI lowers the chance of slow flow/no-reflow in adults with STEMI.

  Recruiting at 2 sites Phase 4 National Institute of Cardiovascular Diseases, Pakistan · Karachi, Sindh and 1 other locations · NCT07536802

• Subclinical depression in people after a first heart attack (SUBDIMA25)

  This project will test how common mild depressive symptoms are in adults hospitalized for a first heart attack and whether those symptoms relate to biomarkers, heart function, and recovery over the next year.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, Italia · NCT07492537

• Long-term follow-up after Hearticellgram-AMI treatment

  We will follow people who got one dose of Hearticellgram-AMI after a heart attack for up to 60 months to see if the treatment stays safe.

  Recruiting Pharmicell Co., Ltd. · Seoul, Gangnam · NCT07400458

• Long-term remote ischemic preconditioning after a heart attack

  This trial will test whether daily brief arm blood‑flow restriction after a recent heart attack can lower the chance of major heart and brain events over the following year for people treated for acute myocardial infarction.

  Recruiting Henan Institute of Cardiovascular Epidemiology · Zhengzhou, Henan · NCT07181356

• Using wearable devices to monitor heart attack patients

  This study tests whether wearable devices can help monitor heart attack patients in the hospital to improve their care and predict their recovery.

  Recruiting RenJi Hospital · Shanghai · NCT06995495

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.